Novonesis stock gains strategic weight with major India enzyme investment

Novonesis stock stands on a solid strategic footing as the Danish biosolutions group commits USD 705.2 million to a new enzyme production facility in India, while investors track its valuation metrics on Nasdaq Copenhagen.

Novonesis stock is drawing investor attention after the Danish biosolutions and biotechnology group (ISIN DK0060336014) committed USD 705.2 million to a major expansion of its enzyme production capacity in India, as reported on September 4, 2026.

Large India investment underpins growth strategy

According to coverage by Home and Personal Care Middle East and Africa, Novonesis will invest Rs 6,660 crore, equivalent to USD 705.2 million, to expand its facility at Patalganga in Maharashtra, India, with an advanced enzyme production plant expected to be fully operational by 2030.

The expansion is designed to increase Novonesis production capacity and support rising demand for biosolutions across industries such as biofuels, household care, and food and beverages. The company states that the Patalganga facility will become part of its global production network, bringing it closer to customers in key emerging markets including India, the wider South Asia region, the Middle East and Africa, which it expects to grow faster than developed markets.

Capacity, sustainability and global footprint

As outlined in the same HPC Middle East and Africa report, Novonesis plans to design the new Patalganga facility to reduce water and energy consumption, including freshwater recycling and integrated heat pumps to lower energy requirements. This sustainability angle reinforces the companys positioning in biosolutions, where environmental performance is a key part of customer value.

The investment in India is part of a broader program to strengthen Novonesis global production footprint. The company has expanded facilities in Rayong in Thailand, Franklinton in North Carolina, Taicang in China, Araucaria in Brazil and West Allis in Wisconsin, demonstrating a multi-continent manufacturing strategy that supports global customers in bioindustrial, food and household applications.

Valuation metrics and market perspective

For investors tracking Novonesis stock on Nasdaq Copenhagen, valuation data compiled by Inderes provide useful context. The overview lists a share price of 371.10 Danish kroner associated with fiscal year 2023 and 407.70 Danish kroner associated with fiscal year 2024, illustrating that the stock has risen by 9.9 percent between those two points based on the median valuation series.

The same Inderes dataset indicates that the corresponding market capitalization values increased from 104,279.1 million Danish kroner for 2023 to 190,925.4 million Danish kroner for 2024, meaning the indicated market cap nearly doubled in the period as the companys share count expanded and investors priced in growth in biosolutions.

Key valuation ratios from the Inderes overview show a price to earnings ratio of 34.0 for 2023 compared with 81.6 for 2024, highlighting that the implied multiple has more than doubled, while the EV to EBIT ratio moved from 27.9 to 54.1 across the same fiscal years. These numbers underline that Novonesis stock is priced as a high growth biosolutions business, with investors paying a premium relative to historical levels.

Representative product and segment focus

Novonesis is best known for its enzyme and biosolution platforms serving industries such as food, beverages, household care and biofuels. Many of its industrial enzyme products are used to improve efficiency and reduce resource use in manufacturing, consistent with the sustainability-focused design of the new Patalganga facility described in the Indian expansion announcement.

Stock context and investor takeaway

As of September 4, 2026, Novonesis stock remains supported by its strategic expansion program and the capital expenditure plan that includes the USD 705.2 million India investment, while investors weigh the high valuation metrics indicated for fiscal year 2024 against the companys long term growth prospects in emerging markets.

Novonesis stock profile

• Company: Novonesis A/S
• ISIN: DK0060336014
• Ticker: NSIS B
• Trading venue: Nasdaq Copenhagen
• Market capitalization: 190,925.4 million DKK (associated with fiscal year 2024 valuation overview)
• Sector / Industry: Health Care / Biotechnology and Pharmaceuticals
• Index membership: Copenhagen market indices including health care sector benchmarks